AMS-17

• UNSPSC Description:

  AMS-17 is a potent NLRP3 inhibitor, inhibiting microglia activation in vitro and in vivo. AMS-17 also inhibits cytokines such as caspase-1, TNF-α, IL-1β and inducible nitric oxide synthase (iNOS) in N9 cells. AMS-17 can be used for researching inflammation-associated neurological disorders[1].

• Target Antigen:

  NOD-like Receptor (NLR)

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/ams-17.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1N(CCCN1S(=O)(C2=CC=C(C=C2)C(F)(F)F)=O)C3=CN=CN=C3

• Molecular Weight:

  386.35

• References & Citations:

  [1]Zhang C, et al. Targeting NLRP3 signaling by a novel-designed sulfonylurea compound for inhibition of microglial inflammation. Bioorg Med Chem.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  3019885-78-7